Zobrazeno 1 - 10
of 22
pro vyhledávání: '"G S Sonke"'
Autor:
M. C. Liefaard, A. van der Voort, M. van Seijen, B. Thijssen, J. Sanders, S. Vonk, L. Mittempergher, R. Bhaskaran, L. de Munck, A. E. van Leeuwen-Stok, R. Salgado, H. M. Horlings, E. H. Lips, G. S. Sonke
Publikováno v:
npj Breast Cancer, Vol 10, Iss 1, Pp 1-9 (2024)
Abstract Tumor-infiltrating lymphocytes (TILs) have been associated with outcomes in HER2-positive breast cancer patients treated with neoadjuvant chemotherapy and trastuzumab. However, it remains unclear if TILs could be a prognostic and/or predicti
Externí odkaz:
https://doaj.org/article/dfc1b1ee02aa46cab23090ed7177554b
Autor:
P. Neven, P. A. Fasching, S. Chia, G. Jerusalem, M. De Laurentiis, S.-A. Im, K. Petrakova, G. V. Bianchi, M. Martín, A. Nusch, G. S. Sonke, L. De la Cruz-Merino, J. T. Beck, J. P. Zarate, Y. Wang, A. Chakravartty, C. Wang, D. J. Slamon
Publikováno v:
Breast Cancer Research, Vol 25, Iss 1, Pp 1-10 (2023)
Abstract Background The phase III MONALEESA-3 trial included first- (1L) and second-line (2L) patients and demonstrated a significant overall survival (OS) benefit for ribociclib + fulvestrant in patients with hormone receptor–positive, human epide
Externí odkaz:
https://doaj.org/article/d5a21e559a8a42ca8ba62ead0fa349e5
Autor:
M. C. Liefaard, A. van der Voort, M. S. van Ramshorst, J. Sanders, S. Vonk, H. M. Horlings, S. Siesling, L. de Munck, A. E. van Leeuwen, M. Kleijn, L. Mittempergher, M. M. Kuilman, A. M. Glas, J. Wesseling, E. H. Lips, G. S. Sonke
Publikováno v:
Breast Cancer Research, Vol 25, Iss 1, Pp 1-15 (2023)
Abstract Background The introduction of pertuzumab has greatly improved pathological complete response (pCR) rates in HER2-positive breast cancer, yet effects on long-term survival have been limited and it is uncertain which patients derive most bene
Externí odkaz:
https://doaj.org/article/bfa7c6239ce5491780fe72525f695abc
Autor:
E. W. Koevoets, S. B. Schagen, M. B. de Ruiter, M. I. Geerlings, L. Witlox, E. van der Wall, M. M. Stuiver, G. S. Sonke, M. J. Velthuis, J. J. Jobsen, M. B. E. Menke-Pluijmers, E. Göker, C. C. van der Pol, M. E. M. M. Bos, L. W. Tick, N. A. van Holsteijn, J. van der Palen, A. M. May, E. M. Monninkhof, PAM study group
Publikováno v:
Breast Cancer Research, Vol 24, Iss 1, Pp 1-13 (2022)
Abstract Background Up to 60% of breast cancer patients treated with chemotherapy is confronted with cognitive problems, which can have a significant impact on daily activities and quality of life (QoL). We investigated whether exercise training impr
Externí odkaz:
https://doaj.org/article/a85d3da1019c4cf9844e8dc54dee61b2
Autor:
R. de Haan, E. van Werkhoven, M.M. van den Heuvel, H. M. U. Peulen, G. S. Sonke, P. Elkhuizen, M. W. M. van den Brekel, M. E. T. Tesselaar, C. Vens, J. H. M. Schellens, B. van Triest, M. Verheij
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-13 (2019)
Abstract Background Poly (ADP-ribose) Polymerase (PARP) inhibitors are promising novel radiosensitisers. Pre-clinical models have demonstrated potent and tumour-specific radiosensitisation by PARP inhibitors. Olaparib is a PARP inhibitor with a favou
Externí odkaz:
https://doaj.org/article/265dba91b78e4b399e364cfbdf77fede
Autor:
A. van Ommen-Nijhof, I. R. Konings, C. J. J. van Zeijl, C. A. Uyl-de Groot, V. van der Noort, A. Jager, G. S. Sonke, On behalf of the SONIA study steering committee
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-7 (2018)
Abstract Background Combining cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors with endocrine therapy is an effective strategy to improve progression-free survival in hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2
Externí odkaz:
https://doaj.org/article/bad234be41ab4652a35025ddb0681877
Publikováno v:
Breast Cancer Research and Treatment. 192:485-489
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2521db69c1244aae8c66f581e77ea9d1
https://doi.org/10.1007/s10549-021-06505-z
https://doi.org/10.1007/s10549-021-06505-z
Autor:
Marielle W. G. Ruijs, M E van Leerdam, Marianne B. Crijns, S A Nieuwenburg, G S Sonke, F. Adan
Publikováno v:
Familial Cancer. 19:347-351
Li-Fraumeni syndrome (LFS) is an inherited cancer syndrome, characterized by an early onset of various types of cancers. LFS is associated with a germline mutation in the TP53 gene. The risk of developing skin cancer in patients with LFS is unknown.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a2c6f0e5acac9806c1b3f5ac015ef771
https://doi.org/10.1007/s10689-020-00178-1
https://doi.org/10.1007/s10689-020-00178-1
Publikováno v:
Breast cancer research and treatment. 192(3)
Endocrine therapy is one of the cornerstones of early breast cancer treatment. While this medication could be initiated on the day of diagnosis, it is often postponed until after completion of surgery, radiotherapy, and chemotherapy. This practice is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::f4edf9fd06835165ee59bb773eb00716
https://pubmed.ncbi.nlm.nih.gov/35132502
https://pubmed.ncbi.nlm.nih.gov/35132502
Autor:
M J A, Rietveld, J, van der Velden, A M, Westermann, W J, van Driel, G S, Sonke, P O, Witteveen, F K, Ploos van Amstel, L F A G, Massuger, P B, Ottevanger
Publikováno v:
The Netherlands journal of medicine. 78(6)
Combined administration of intravenous (iv) and intraperitoneal (ip) (iv/ip) chemotherapy is an effective adjuvant treatment option after primary debulking surgery (PDS) for advanced ovarian cancer (OC). Increased toxicityand patient burden limit its
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::ddac366d786e04a4e78386d0ce058519
https://pubmed.ncbi.nlm.nih.gov/33380532
https://pubmed.ncbi.nlm.nih.gov/33380532